Each biotech start-up has its own dynamics and need, which cannot be generalized. (Photo Courtesy: www. prophotostock.deviantart.com)
Dr Mrutyunjay (Jay) Suar, the director of the school of biotechnology, KIIT University, and CEO of KIIT-TBI, shares some of his revealing insights into the incubator's model and uniqueness, success stories and the roadmap on how to kick-start the biotech boom in the next couple of years in the nation.
Q: What is the incubation model that you follow at your TBI?
Dr Jay: Being primarily a University-based incubator; we focus on translating research entrepreneurial avenues. We mostly encourage ‘Technology Platform Model' wherein start-ups sell or rent technologies to various established players.
However, more recently, we are also getting into the Research Intensive (or royalty income) Pharmaceutical Companies or RIPCO (start-ups that research and develop a new product to finally license it to a big pharma or biotech company in exchange for a royalty on sales); and Fully Integrated Pharmaceutical Company or FIPCO (start-ups that launch their own product) models as well.
We also know that no single model can be followed in an incubator, and that's the reason we are competitive to nurture diversified innovative ideas to translate into a product or process with high commercial values.